How Type 2 Inflammation Influences Treatment Choices

Panelists discuss how identifying type 2 inflammation in patients influences treatment decisions by steering clinicians toward targeted therapies, such as biologics or other immunomodulators, that specifically address the underlying inflammatory mechanisms rather than relying solely on symptomatic treatments.

EP: 1.Navigating the Challenges of Respiratory Diseases

EP: 2.The Impact of Atopic Dermatitis and Prurigo Nodularis

EP: 3.Linking Type 2 Inflammation to Asthma and COPD

EP: 4.Impact of Exacerbations in Type 2 Inflammatory Respiratory Diseases

EP: 5.Type 2 Inflammation: The Link Between AD and PN

EP: 6.Personalizing Treatment Selection

EP: 7.Navigating Treatment Challenges in Chronic Skin Conditions

EP: 8.Role of Biologics in Dermatological Care

EP: 9.Biomarkers as Tools in Management of Type 2 Inflammation

EP: 10.Strategies to Manage Type 2 Inflammation in Respiratory Diseases

EP: 11.Addressing Unmet Needs and Emerging Agents

EP: 12.Future Directions for Type 2 Inflammation Management

EP: 13.Type 2 Inflammatory Diseases and Impact on Quality of Life

EP: 14.Type 2 Inflammation Biomarkers

Now Viewing

EP: 15.How Type 2 Inflammation Influences Treatment Choices

EP: 16.Complications of Uncontrolled Disease and Management of Comorbidities

EP: 17.Patient Education and Emerging Therapies

EP: 18.Unmet Needs and Future Research

• In your experience, how does knowing a patient has type 2 inflammation influence the choice in treatment?

Related Videos

Related Content

Advertisement

March 11th 2025

Overdiagnosis of Adult ADHD Is Exacerbating the Stimulant Shortage

Salayna M. Abdallah, MA, BS Bryce L. Tipton, BS Joel W. Hughes, PhD

The authors argue that the stimulant shortage is being perpetuated by the overdiagnosis of attention-deficit/hyperactivity disorder (ADHD) in adults because executive functioning deficits are not included in diagnostic criteria.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

March 9th 2025

Reviving the Classics: The Role of Older Medications in Modern Dermatology

Brooke McCormick

Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

March 8th 2025

Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment

Brooke McCormick

Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).

March 8th 2025

Improving Social Determinants of Health Essential for Better AD Outcomes in Pediatric Patients of Color

Brooke McCormick

Amid limited access to pediatric dermatologists nationwide, pediatric patients of color with atopic dermatitis (AD) are particularly affected by social determinants of health, further impacting their outcomes.

Related Content

Advertisement

March 11th 2025

Overdiagnosis of Adult ADHD Is Exacerbating the Stimulant Shortage

Salayna M. Abdallah, MA, BS Bryce L. Tipton, BS Joel W. Hughes, PhD

The authors argue that the stimulant shortage is being perpetuated by the overdiagnosis of attention-deficit/hyperactivity disorder (ADHD) in adults because executive functioning deficits are not included in diagnostic criteria.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

March 9th 2025

Reviving the Classics: The Role of Older Medications in Modern Dermatology

Brooke McCormick

Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

March 8th 2025

Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment

Brooke McCormick

Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).

March 8th 2025

Improving Social Determinants of Health Essential for Better AD Outcomes in Pediatric Patients of Color

Brooke McCormick

Amid limited access to pediatric dermatologists nationwide, pediatric patients of color with atopic dermatitis (AD) are particularly affected by social determinants of health, further impacting their outcomes.